Oriheal Vetrocetam Levetiracetam Oral Solution for Dogs & Cats | Epilepsy, Seizure Control & Neurological Disorder Management | 100ml Veterinary Prescription

Prescription Required — For veterinary use only. Administer strictly under the supervision of a licensed veterinarian.

Oriheal Vetrocetam Levetiracetam Oral Solution for Dogs & Cats (100ml)

Oriheal Vetrocetam is a veterinary prescription oral anticonvulsant solution containing Levetiracetam, a second-generation antiepileptic drug (AED) with a unique mechanism of action via synaptic vesicle glycoprotein 2A (SV2A) binding, manufactured by Oriheal Lifesciences. Available as a 100ml palatable oral solution for accurate ml-based, weight-adjusted dosing in dogs and cats. Levetiracetam is one of the most widely prescribed anticonvulsants in small animal veterinary neurology, used as monotherapy for idiopathic epilepsy or as adjunct therapy alongside phenobarbitone or potassium bromide in refractory or poorly controlled seizures.

Composition (per ml — confirm concentration from label)

• Levetiracetam — concentration mg/ml (confirm from product label) — second-generation anticonvulsant / antiepileptic
• Palatable oral solution base — q.s. to 100ml

Mechanism of Action

• Levetiracetam binds selectively to Synaptic Vesicle Glycoprotein 2A (SV2A) — a transmembrane protein on synaptic vesicles involved in vesicle exocytosis and neurotransmitter release regulation
• SV2A binding modulates neurotransmitter release at presynaptic terminals — reduces excessive synchronised neuronal firing that characterises epileptic seizures
• Unique mechanism entirely distinct from all other AEDs (does not act on sodium channels, GABA receptors, or calcium channels) — no pharmacokinetic drug interactions via cytochrome P450 enzymes; particularly safe in polypharmacy seizure management

Therapeutic Class

• Veterinary second-generation anticonvulsant / antiepileptic prescription oral solution for dogs and cats — epilepsy and seizure management

Key Benefits

• SV2A-selective mechanism — unique non-sodium-channel, non-GABA anticonvulsant; effective where first-generation AEDs have failed or caused adverse effects
• No cytochrome P450 interactions — minimal pharmacokinetic drug interactions; safe to combine with phenobarbitone and potassium bromide in refractory epilepsy
• Oral solution format — accurate ml-based weight-adjusted dosing; easier administration for cats and small dogs vs. tablets
• Lower hepatotoxicity risk compared to phenobarbitone — suitable for long-term use with appropriate monitoring

Indications

• Idiopathic epilepsy (primary epilepsy) in dogs and cats — monotherapy
• Structural and reactive epilepsy — adjunct to phenobarbitone or potassium bromide in refractory or poorly controlled seizures
• Cluster seizures and status epilepticus prevention in dogs and cats
• Seizure management in animals where phenobarbitone is contraindicated (hepatic disease) or causing unacceptable adverse effects

Directions for Use

• Administer orally as directed by a licensed veterinarian — measure dose accurately with an oral syringe
• Dosage determined by species, body weight, seizure type, and whether used as monotherapy or adjunct — refer to veterinary prescription
• Do not abruptly discontinue — sudden withdrawal may precipitate rebound seizures; taper dose under veterinary supervision if discontinuing

Safety Information

• Prescription medicine — for veterinary use only; administer under licensed veterinary supervision
• Most common adverse effects: sedation, ataxia, and behavioural changes (aggression or anxiety reported in some dogs) — usually transient on initiation; report to veterinarian if persistent or severe
• Renally excreted — dose reduction may be required in animals with renal impairment; monitor renal function on long-term therapy
• Do not abruptly stop — risk of rebound seizures on sudden discontinuation; always taper under veterinary guidance
• Keep out of reach of children; store in a cool, dry place away from direct sunlight; keep bottle tightly closed after use